Compare Boston Scientific Corporation (BSX) vs Equinix Inc (EQIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Equinix Inc — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while Equinix Inc trades at $1,025 (market cap $100.95B). The key difference: Equinix Inc is the larger of the two by market cap, and Equinix Inc pays a 1.92% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | EQIX | |
|---|---|---|
Market Cap | $66.37B | $100.95B |
Sector | Health | Real Estate |
52-Week High | $108.14 | $1.12K |
52-Week Low | $42.63 | $726.09 |
Enterprise Value | $75.94B | $121.23B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
EQIX trades at $1,039.53, down 1.11% on the day, with a bullish technical signal and strong analyst support (74.51% buy ratings). Revenue grew to $9.22B in 2025, with net income reaching $1.35B, though recent quarters showed mixed earnings results. The company benefits from AI infrastructure demand, evidenced by partnerships with Cisco and NVIDIA (Business Wire, 2026-06-17).
Outlook remains positive due to recurring revenue growth and AI tailwinds, but high valuation (P/E 71.89) and negative cash flow (-$1.26B in 2025) pose risks. Debt levels are rising, with debt-to-asset ratio at 47.13% in 2025. The consensus price target of $1,110 suggests upside potential if execution aligns with AI-driven demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
